10.02.2013 Views

Presentation Outline ICHP Annual Meeting September 13-15

Presentation Outline ICHP Annual Meeting September 13-15

Presentation Outline ICHP Annual Meeting September 13-15

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Cumulative Pain Score through 72 Hours<br />

Cumulativ ve Pain Score<br />

Gorfine et al. Dis Colon Rectum. 2011;54:<strong>15</strong>52-9.<br />

P < 0.0001<br />

No Opioid Rescue Medications vs Hours<br />

Gorfine et al. Dis Colon Rectum. 2011;54:<strong>15</strong>52-9.<br />

Liposomal bupivacaine 300 mg<br />

Placebo<br />

FDA Review<br />

“Between 24 and 72 hours after study drug<br />

administration, there was minimal to no<br />

difference between EXPAREL and placebo<br />

treatments on mean pain intensity; however,<br />

there was an attendant decrease in opioid<br />

consumption, the clinical benefit of which was<br />

not demonstrated.”<br />

Mean Total Amount of Opioids Over 72 Hr<br />

Milligramss<br />

(mg)<br />

Gorfine et al. Dis Colon Rectum. 2011;54:<strong>15</strong>52-9.<br />

Marketing<br />

P < 0.006<br />

“One dose of Exparel provides up to 72 hours of<br />

postsurgical pain control with a decrease in<br />

opioid consumption without the need for<br />

catheters or pumps.”<br />

Safety<br />

• No primary safety outcome defined<br />

• Identified opioid‐ related adverse effects<br />

8/29/2012<br />

3

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!